yttrium (90Y) clivatuzumab tetraxetan

Home
Ligands
yttrium (90Y) clivatuzumab tetraxetan

GtoPdb Ligand ID: 8087

Synonyms: 90Y-hPAM4 | hPAM4 [3] | hPAM4-Cide | IMMU-107

Comment: This antibody is conjugated to tetraxetan (DOTA) which acts as a chelating agent for the radioisotope yttrium 90. This antibody conjugate is a radioimmunotherapy agent designed for the treatment of pancreatic cancer [6].

References
1. Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, Büchler MW, Aubert JP, Batra SK. (2001) Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res, 7 (12): 4033-40. [PMID:11751498]
2. Gold DV, Newsome G, Liu D, Goldenberg DM. (2013) Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol Cancer, 12 (1): 143. [PMID:24257318]
3. Goldenberg DM, Hansen H, Qu Z. (2004) Humanized monoclonal antiboby hpam4. Patent number: WO2003106495. Assignee: Immunomedics Inc.. Priority date: 14/06/2002. Publication date: 01/04/2004.
4. Goldenberg DM, Hansen HJ, Qu Z. (2007) Monoclonal antibody hPAM4. Patent number: US7282567. Assignee: Immunomedics, Inc.. Priority date: 14/06/2002. Publication date: 16/10/2007.
5. Gulec SA, Cohen SJ, Pennington KL, Zuckier LS, Hauke RJ, Horne H, Wegener WA, Teoh N, Gold DV, Sharkey RM et al.. (2011) Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial. Clin Cancer Res, 17 (12): 4091-100. [PMID:21527562]
6. Han S, Jin G, Wang L, Li M, He C, Guo X, Zhu Q. (2014) The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy. J Immunol Res, 2014: 268479. [PMID:24818166]
7. Liu D, Chang CH, Gold DV, Goldenberg DM. (2015) Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer. Oncotarget, 6 (6): 4274-85. [PMID:25595893]
8. Niv Y. (2008) MUC1 and colorectal cancer pathophysiology considerations. World J Gastroenterol, 14 (14): 2139-41. [PMID:18407586]
9. Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ et al.. (2012) Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer, 118 (22): 5497-506. [PMID:22569804]
10. Ringel J, Löhr M. (2003) The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol Cancer, 2: 9. [PMID:12556240]
11. Singh AP, Chauhan SC, Bafna S, Johansson SL, Smith LM, Moniaux N, Lin MF, Batra SK. (2006) Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate, 66 (4): 421-9. [PMID:16302265]
12. Torres MP, Chakraborty S, Souchek J, Batra SK. (2012) Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des, 18 (17): 2472-81. [PMID:22372499]

References

1. Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, Büchler MW, Aubert JP, Batra SK. (2001)
Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance.
Clin Cancer Res, 7 (12): 4033-40. [PMID:11751498]

2. Gold DV, Newsome G, Liu D, Goldenberg DM. (2013)
Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.
Mol Cancer, 12 (1): 143. [PMID:24257318]

3. Goldenberg DM, Hansen H, Qu Z. (2004)
Humanized monoclonal antiboby hpam4.
Patent number: WO2003106495. Assignee: Immunomedics Inc.. Priority date: 14/06/2002. Publication date: 01/04/2004.

4. Goldenberg DM, Hansen HJ, Qu Z. (2007)
Monoclonal antibody hPAM4.
Patent number: US7282567. Assignee: Immunomedics, Inc.. Priority date: 14/06/2002. Publication date: 16/10/2007.

5. Gulec SA, Cohen SJ, Pennington KL, Zuckier LS, Hauke RJ, Horne H, Wegener WA, Teoh N, Gold DV, Sharkey RM et al.. (2011)
Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.
Clin Cancer Res, 17 (12): 4091-100. [PMID:21527562]

6. Han S, Jin G, Wang L, Li M, He C, Guo X, Zhu Q. (2014)
The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy.
J Immunol Res, 2014: 268479. [PMID:24818166]

7. Liu D, Chang CH, Gold DV, Goldenberg DM. (2015)
Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer.
Oncotarget, 6 (6): 4274-85. [PMID:25595893]

8. Niv Y. (2008)
MUC1 and colorectal cancer pathophysiology considerations.
World J Gastroenterol, 14 (14): 2139-41. [PMID:18407586]

9. Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ et al.. (2012)
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Cancer, 118 (22): 5497-506. [PMID:22569804]

10. Ringel J, Löhr M. (2003)
The MUC gene family: their role in diagnosis and early detection of pancreatic cancer.
Mol Cancer, 2: 9. [PMID:12556240]

11. Singh AP, Chauhan SC, Bafna S, Johansson SL, Smith LM, Moniaux N, Lin MF, Batra SK. (2006)
Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas.
Prostate, 66 (4): 421-9. [PMID:16302265]

12. Torres MP, Chakraborty S, Souchek J, Batra SK. (2012)
Mucin-based targeted pancreatic cancer therapy.
Curr Pharm Des, 18 (17): 2472-81. [PMID:22372499]